CLINICAL TRIALS PROFILE FOR BIAXIN XL

All Clinical Trials for BIAXIN XL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006219 ↗	Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 2	2000-08-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma.
NCT00006219 ↗	Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma	Completed	Mayo Clinic	Phase 2	2000-08-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma.
NCT00151203 ↗	Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma	Completed	Celgene Corporation	Phase 2	2004-12-01	PRIMARY STUDY OBJECTIVES - To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). - To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES - To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone and lenalidomide. - To examine the angiogenesis profile in untreated patients and in patients receiving induction therapy.
NCT00151203 ↗	Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma	Completed	Weill Medical College of Cornell University	Phase 2	2004-12-01	PRIMARY STUDY OBJECTIVES - To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). - To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES - To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone and lenalidomide. - To examine the angiogenesis profile in untreated patients and in patients receiving induction therapy.
NCT00182663 ↗	Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant	Completed	National Cancer Institute (NCI)	Phase 2	2003-06-01	This phase II trial studies the side effects and how well giving thalidomide, dexamethasone, and clarithromycin together works in treating patients with multiple myeloma previously treated with transplant. Biological therapies, such as thalidomide and clarithromycin, may stimulate the immune system in different ways and stop cancer cells from growing. Dexamethasone also works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving thalidomide together with dexamethasone and clarithromycin after a transplant may be an effective treatment for multiple myeloma
NCT00182663 ↗	Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant	Completed	Fred Hutchinson Cancer Research Center	Phase 2	2003-06-01	This phase II trial studies the side effects and how well giving thalidomide, dexamethasone, and clarithromycin together works in treating patients with multiple myeloma previously treated with transplant. Biological therapies, such as thalidomide and clarithromycin, may stimulate the immune system in different ways and stop cancer cells from growing. Dexamethasone also works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving thalidomide together with dexamethasone and clarithromycin after a transplant may be an effective treatment for multiple myeloma
NCT00205634 ↗	Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis	Completed	Abbott	Phase 2	2000-12-01	The purpose of this study is to evaluate whether Biaxin (clarithromycin) improves sputum abnormalities, lung function, and overall feeling of well-being in people with cystic fibrosis (CF). Biaxin is an antibiotic commonly used for the treatment of respiratory infections in people who do not have CF, and is sometimes used in CF patients as well. Studies done in a disease called diffuse panbronchiolitis (which is similar to CF) and some preliminary studies that have been done in CF patients suggest that Biaxin might have a beneficial effect on CF sputum in ways unrelated to its antibiotic activity.

Clinical Trial Conditions for BIAXIN XL

Condition Name

Condition Name for BIAXIN XL
Intervention	Trials
Healthy	13
Multiple Myeloma	10
Idiopathic Hypersomnia	2
Infection	2

Condition MeSH

Condition MeSH for BIAXIN XL
Intervention	Trials
Neoplasms, Plasma Cell	15
Multiple Myeloma	15
Pneumonia	3
Aggression	2

Clinical Trial Locations for BIAXIN XL

Trials by Country

Trials by Country for BIAXIN XL
Location	Trials
United States	97
China	24
Canada	19
Korea, Republic of	4
India	3

Trials by US State

Trials by US State for BIAXIN XL
Location	Trials
New York	9
Arizona	7
Missouri	6
Washington	6
Texas	5

Clinical Trial Progress for BIAXIN XL

Clinical Trial Phase

Clinical Trial Phase for BIAXIN XL
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	10
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for BIAXIN XL
Clinical Trial Phase	Trials
Completed	37
Recruiting	4
Active, not recruiting	4

Clinical Trial Sponsors for BIAXIN XL

Sponsor Name

Sponsor Name for BIAXIN XL
Sponsor	Trials
Abbott	6
Ranbaxy Laboratories Limited	5
Weill Medical College of Cornell University	5

Sponsor Type

Sponsor Type for BIAXIN XL
Sponsor	Trials
Industry	43
Other	40
NIH	6

Biaxin XL (clarithromycin) Clinical Trials Update, Market Analysis, and Projection

Last updated: April 26, 2026

What is Biaxin XL and how is it used in clinical practice?

Biaxin XL is an extended-release formulation of clarithromycin (a macrolide antibiotic). In practice, it is used for bacterial infections where macrolide therapy is appropriate, with dosing and indication specifics tied to each approved label and country.

Regulatory posture: Biaxin (immediate-release clarithromycin) and related formulations are long-established products. Biaxin XL is not positioned as a new mechanism or late-stage pipeline asset; it is primarily a legacy antibiotic brand/formulation with ongoing label maintenance rather than a modern blockbuster-style development program.

---

What does the clinical trials landscape look like for Biaxin XL?

No active late-stage registrational program for Biaxin XL is evident from mainstream clinical-trials registries in the recent era. The practical reality for “clinical trials update” on a legacy formulation is that the majority of meaningful evidence is from earlier periods (bioequivalence, formulation performance, pharmacokinetics, and clinical comparisons versus immediate-release clarithromycin), with limited modern interventional trials.

Clinical evidence types that matter for a legacy extended-release antibiotic

For products like Biaxin XL, the recurring trial categories are:

• Bioequivalence and pharmacokinetic studies comparing extended-release versus immediate-release clarithromycin.
• Clinical efficacy comparisons in prior respiratory or other labeled bacterial infection populations.
• Safety monitoring focused on macrolide-class adverse events (gastrointestinal effects, QT-related risk in appropriate contexts, drug interaction profile).

What to expect in a “current” update

For business and R&D tracking, the signal to monitor is not “new Phase 3 efficacy,” but rather:

• Label changes (safety communications, dosing refinements)
• Formulary and access changes (health technology assessments, tender cycles, payer edits)
• Generic competition evolution (market share impact)

Given the drug’s legacy status, near-term development activity is typically limited to post-marketing commitments or local regulatory updates, not novel Phase 3 readouts.

---

How big is the Biaxin XL market and where does demand come from?

Biaxin XL competes within the broader macrolide antibiotic market (clarithromycin class), which is driven by:

• Respiratory infection management (where macrolides are still prescribed based on guideline fit and local resistance patterns)
• Niche indications tied to guideline pathways and historical prescribing habits
• Access and reimbursement dynamics (hospital formularies, outpatient antibiotic policies)

Market structure

The clarithromycin market is characterized by:

• High generic penetration (clarithromycin is off-patent in most jurisdictions)
• Brand/formulation competition primarily on tolerability and dosing convenience (extended-release versus immediate-release adherence considerations)
• Local resistance and guideline shifts changing macrolide utilization rates over time

Biaxin XL share dynamics (what moves the needle)

For a brand like Biaxin XL, unit demand is usually less about clinical superiority and more about:

• Generic pricing pressure
• Contracting and tender outcomes
• Inventory and supply continuity
• Antibiotic stewardship restrictions in outpatient and hospital settings

---

What is the competitive threat profile for Biaxin XL?

1) Generic clarithromycin dominates

Extended-release clarithromycin products face direct substitutes from:

• Generic clarithromycin (including immediate-release and, in some markets, extended-release variants)
• Alternative antibiotic classes used per guideline and local resistance patterns

2) Macrolide class headwinds

Across many markets, macrolide prescribing faces:

• Stewardship restrictions where resistance and guideline positioning tighten
• Reduced empirical use in some respiratory indications
• Safety and interaction scrutiny (especially where QT and drug interaction risks lead to more cautious selection)

3) Relative positioning of extended-release

Extended-release tablets can retain some value when:

• Dosing convenience improves adherence
• Payer policies or formularies favor once-daily schedules
• Tolerability profiles support continued prescribing

In most cases, however, the extended-release advantage is not enough to offset generic pricing and stewards-driven utilization declines.

---

What market outlook and projections are most defensible for the next 5 years?

A defensible projection for Biaxin XL, given its legacy status and likely generic competition, is a structural decline in brand share with volatility tied to prescribing policies. The most credible forecast shape is:

• Near-term stability in some contracted markets
• Ongoing share erosion from generic substitution
• Low-to-moderate total category growth at best, with much driven by guideline and resistance shifts

Projection framework (how to translate this into actionable numbers)

Use three levers:

1. Category demand trend (macrolide utilization by indication)
2. Competitive pressure (generic price index and formulary access)
3. Formulation value (extended-release retention where once-daily dosing is preferred)

Expected trajectory (directional)

For business planning:

• Revenue: tends to flatten or decline in brand terms as generics undercut pricing.
• Volumes: track category prescribing; can be stable in constrained formularies, otherwise drift downward.
• Margin: compresses as contracting and discounts intensify.

Quantitative projections cannot be produced from the information available in this request.

---

What regulatory, label, and safety factors affect ongoing commercialization?

For clarithromycin-based products, major operational risks include:

• Safety communications and class warnings that can alter prescribing behavior
• Drug-drug interaction management in real-world practice
• Local regulatory re-affirmations of indications and dosing

For Biaxin XL specifically, the extended-release formulation adds operational considerations around:

• Prescribing instructions and substitution policies
• Bioavailability and equivalence standards in generic substitution

---

Key Takeaways

• Biaxin XL is a legacy clarithromycin extended-release antibiotic with clinical evidence concentrated in earlier bioequivalence and efficacy studies rather than an active modern late-stage development pipeline.
• Market performance is primarily driven by generic competition and prescribing policy, not differentiation via new clinical outcomes.
• Near-term outcomes are likely to be stable in contracted settings but structurally challenged by ongoing generic substitution and macrolide stewardship headwinds.
• A credible 5-year projection requires hard market inputs (units, pricing, category trend, and country-level formulary data); those inputs are not provided here, so only directional guidance is supportable.

---

FAQs

1. Is Biaxin XL in active Phase 3 development?
   No active late-stage registrational program is indicated in mainstream public trial tracking for the extended-release brand.

2. What is the main competitive threat to Biaxin XL?
   Generic clarithromycin, including price and formulary substitution, is the primary driver.

3. What determines whether Biaxin XL retains share versus generics?
   Contracting, tender outcomes, and payer/formulary rules that preserve extended-release prescribing.

4. Do macrolide safety and stewardship policies affect Biaxin XL?
   Yes. Class-level interaction and resistance-guided prescribing trends can reduce use in some settings.

5. Can a precise 5-year revenue forecast be generated from this prompt?
   Not without quantitative market inputs such as category volume trend, pricing history, and country-level share.

---

References

[1] U.S. Food and Drug Administration. Clarithromycin drug information (labeling and safety-related communications). https://www.fda.gov/
[2] European Medicines Agency. Medicines and clarithromycin-related product information. https://www.ema.europa.eu/
[3] ClinicalTrials.gov. Search results for clarithromycin extended-release / Biaxin XL. https://clinicaltrials.gov/